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Abstract: Background: Angiogenesis plays an important role in colorectal cancer (CRC) tumorigenesis
and metastatic progression. Methods: The present series consisted of CRC lymph node metastasis
(LNM) tissue samples from 210 patients. Archival paraffin embedded LNM tissue were used to
build up tissue microarray blocks and VEGF expression was immunohistochemically assessed.
Results: VEGF-A and VEGF-C are overexpressed in LNM. VEGF-A was associated with patient
age (p < 0.001), and VEGFR-2 and VEGFR-3 with CRC relapse (p = 0.032; p = 0.030, respectively).
VEGF-C positivity was associated with VEGFR-3 positivity (p = 0.031), and VEGF-D with VEGFR-2
and VEGFR-3 (p ≤ 0.001). Matching the expression in LNM with CRC, in CRC VEGF-A positivity
associates with VEGF-A, VEGF-C, VEGF-D, VEGF-R2, VEGF-R3 positivity in LNM; CRC VEGF-C
with VEGF-D, VEGFR-2, VEGFR-3; CRC VEGFR-2 with VEGF-A, VEGF-C, VEGF-D, VEGFR-2,
VEGFR-3; CRC VEGFR-3 with VEGF-A, VEGF-C, VEGF-D, VEGFR-2, VEGFR-3 in LNM. Conclusion:
This study provides new information, revealing that VEGF family expression is increased in LNM.
The association between the expression of VEGFR-2 and VEGFR-3 in LNM with CRC relapse reveals
its impact on patient prognosis. Interesting data were found when the relationship between these
proteins in primary tumor and their metastasis, were analyzed; VEGFA positivity in primary tumor
is positively related to VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 in their respective LNM
suggesting mutual influence.
Keywords: colorectal cancer; lymph node metastasis; VEGF
1. Introduction
Colorectal cancer (CRC) is the third most common cancer and the fourth most frequent cause of
cancer deaths worldwide [1], being one of the most prevalent diseases of the occidental world [2].
There are some well-established prognostic factors in CRC. Pre-operative tumor staging provides
essential and relevant prognostic information for choosing adequate therapeutic proceeding, being
the factor that best predicts patient survival [3]. Other robust determinants of prognosis include
lymphovascular invasion, positive surgical margins, pre-operative increasing of carcinoembryonic
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antigen (CEA) [4]. However, although these clinicopathological parameters determine the management
of patients, they are not reliable predictors of treatment outcome. Hence, in order to improve clinical
care and patient’s survival, the molecular pathways of cancer dissemination and their biological
markers expression should be identified [1].
Angiogenesis plays an important role in tumorigenesis and metastatic progression of cancer [5].
Actually, the relationship between tumor angiogenesis with the grade of tumor differentiation,
its metastatic potential and prognosis is mentioned in several studies [5]. Neovascularization promotes
tumor growth by supplying nutrients, oxygen and releasing growth factors that promote tumor cell
proliferation [6]. Furthermore, the immature neovasculature facilitates cancer cell entry into the
systemic blood circulation and hence distant metastasis [7].
The regulation of tumor angiogenesis depends on a complex balance between angiogenic and
antiangiogenic factors, secreted by both tumor cells and immune host-infiltrating cells as well as by
tumoral stroma-cells [5–7]. The understanding of the fundamental role of angiogenesis in cancer
growth and metastasis has led to tremendous interest in research in its regulatory mechanisms and
clinical implications in the management of cancer treatment.
Vascular endothelial growth factor (VEGF) is the most widely studied and best characterized
angiogenic factor, secreted by almost all solid cancers [6,7]. It stimulates endothelial proliferation
and migration, vascular permeability and is the most potent angiogenic protein known [5,6,8–10].
The effect of VEGF depends on tumor cell expression of VEGF and its receptors in the endothelial
cells [11]. The ligands of the VEGF family include VEGF-A, VEGF-B, VEGF-C, VEGF-D and VEGF-E
and their receptors (VEGFR-1, VEGFR-2, and VEGFR-3) [12].
When overexpressed, VEGF is associated with advanced tumor stage or tumor invasiveness in
various types of human cancer [13]. CRC growth and spread are dependent on angiogenesis with
VEGF being the most important cytokine involved in the process [8].
Both VEGF and its receptors are expressed at high levels in metastatic CRC and in tumor-associated
endothelial cells, respectively. VEGF expression is higher in patients with metastatic tumors than in
those with non-metastatic tumors [9]. However, the relationship between VEFG tumor expression and
CRC outcomes is controversial. While some studies show that VEGF expression has no significant
prognostic value [10,13–15], others, have demonstrated that the VEGF overexpression in colonic cancer
tissue and lymph nodes indicates more advanced cancer stage and poor prognosis [13,16].
Our previous study reported that the expression of VEGF in the primary tumor was associated
with poor prognosis and reduced patient survival with CRC [13]. This finding was also reinforced by
other studies that consider VEGF expression as a useful marker for prognosis due to its correlation with
angio-lymphatic invasion, lymph node status and depth of local invasion [5,13]. Therefore, it becomes
relevant to evaluate VEGF status in LNM of CRC patients and correlate this expression in lymph node
with primary tumor and clinicopathological characteristics and disease outcome.
2. Results
2.1. Characterization of the Sample
Table 1 describes the clinicopathological data and follow-up results of the 210 patients with
diagnosis of CRC with lymph node metastasis.
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Table 1. Clinicopathological characterization of sample.
Clinical Data and Pre-Operative Exams Results n (%)
Gender Male 131 (62.4)
Female 79 (37.6)
Age (years) ≤45 15 (7.1)
>45 195 (92.9)
Personal history of CRC Negative 182 (86.7)
Positive 28 (13.3)
Familiar history of CRC Negative 172 (81.9)
Positive 22 (10.5)
Clinical presentation Asymptomatic 37 (17.6)
Symptomatic 173 (82.4)
Tumor localization Right colon 50 (23.8)
Left colon 111 (52.9)
Rectum 49 (23.3)
Preoperative value of CEA ≤10 ng/mL 134 (63.8)
>10 ng/mL 38 (18.1)
Metastasis at diagnosis Yes 70 (33.3)
No 140 (66.7)
Histopathological report
Tumor size (mm) ≤45 118 (56.2)
>45 79 (37.6)





Tumor Histological type Adenocarcinoma 179 (85.2)
Mucinous 27 (12.9)
Signet ring cells and mucinous areas 4 (1.9)





Invasion of lymphatic vessels Absent 19 (9)
Present 172 (82)
Invasion of venous vessels Absent 70 (33.3)
Present 132 (62.9)
Tumor staging Stage III 160 (76.2)
Stage IV 50 (23.8)
Follow-up data
Relapse Yes 45 (21.4)
No 165 (78.6)
Death Alive 106 (50.5)
Dead 104 (49.5)
2.2. VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 Expression in CRC Lymph Nodes Metastasis
Table 2 summarizes the frequency of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 positive
expression in lymph nodes metastasis of CRC. VEGF-A was positively expressed in 59.0% of the
evaluated cases, followed by VEGF-C in 54.8% of the cases.
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Table 2. Frequencies of positive VEGF family immunoreactions in the CRC LNM.
Protein Marker
Immunoreaction
n n Positive (%)
VEGF-A 136 124 (59.0%)
VEGF-C 133 115 (54.8%)
VEGF-D 113 88 (41.9%)
VEGFR-2 64 53 (25.2%)
VEGFR-3 104 83 (39.5%)
n: total number of cases with and without VEGF expression; n positive (%): total number of cases with VEGF
expression and respective percentage.
Figure 1 shows representative positive staining for VEGF-A, VEGF-C, VEGF-D, VEGFR-2
and VEGFR-3.
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Figure 1. Immunohistochemical expression of VEGF-A, VEGF-C, VEGF-R2 and VEGF-R3 in. RC LNM
samples (original magnification ×100). (A) positive i munohistochemical expression of VEGF-A with
intensity 2 and exte sion 1; (B) positive im uno chemical expression of VEGF-C w h intensity
3 and extension 3; (C) positive immunohistochemical expression of VEGF-D with intensity 2 and
extension 3; (D) positive immunohistochemical expression of VEGFR-2 with intensity 2 and extension
3 and (E) positive immunohistochemical expression of VEGFR-3 with intensity 3 and extension 3.
2.3. Associations between VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 Expression in Lymph Nodes
Metastasis of CRC and Clinicopathological Characteristics
In order to assess the value of the expression of these angiogenic factors, we sought for associations
with the patients clinicopathological data. An assessment of the correlation between the expression
of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 and the clinical data revealed a significant
association (p = 0.001) between VEGF-A xpr ion and patient age, which was greater in patients
aged older than 45 years (93.8%) compared to patients younger or with 45 years old (42.9%). There is
also an association between the expression of VEGFR-2 (p = 0.032) and VEGFR-3 (p = 0.030) with CRC
relapse. No significant relationship was found for the other analyzed parameters. These results are
shown in Table 3.
When analysing the correlation between these markers with data from diagnosis/surgery,
like patient gender and age, personal or familiar history and follow-up data like relapse and death no
significant association was found, as observed in Table 4.
When analysing the correlation between these markers with data from pathological data,
no significant association was found, as observed in Table 5.
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Table 3. Assessment of correlation between CRC lymph node metastasis VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 expression and clinical data. * Examined
for statistical significance using Fisher’s exact test (when n < 5). In bold the significant results.
Protein Marker
VEGF-A VEGF-C VEGF-D VEGFR-2 VEGFR-3



















0.453Female 53 88.7 47 89.4 38 81.6 23 91.3 37 83.8
Age, years






















































0.708Dead 44 90.9 44 86.4 38 76.3 15 66.7 36 77.8
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Table 4. Assessment of correlation between CRC lymph node metastasis VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 expression and diagnostic/surgical data.
* Examined for statistical significance using Fisher’s exact test (when n < 5).
Protein Marker
VEGF-A VEGF-C VEGF-D VEGFR-2 VEGFR-3



















0.513 *Symptomatic 111 91.9 111 86.5 98 77.6 50 84 87 78.2
Localization









0.213Left Colon 70 91.4 68 91.2 59 78 35 77.1 50 86
Rectum 35 88.6 30 76.7 23 73.9 11 90.9 22 68.2
Metastasis





















Ulcerative 35 82.9 30 93.3 28 71.4 24 75 30 86.7
Infiltrative 15 86.7 13 84.6 10 100 5 80 11 90.9
Exophytic 10 80 15 80 14 78.6 5 80 12 50












>10 26 88.5 25 88 21 85.7 12 91.7 22 86.4
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Table 5. Assessment of correlation between CRC lymph node metastasis VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 pathological data. * Examined for
statistical significance using Fisher’s exact test (when n < 5).
Protein Marker
VEGF-A VEGF-C VEGF-D VEGFR-2 VEGFR-3































0.535Mucinous 15 86.7 17 76.5 16 75 11 81.8 13 69.2
Signet ring cells and












Moderate 60 88.3 55 87.3 49 83.7 29 79.3 43 83.7
Poor 19 94.7 24 83.3 21 66.7 11 81.8 19 68.4






















0.576Present 84 88.1 87 87.4 75 77.3 42 81 68 80.9
TNM stage









0.693Stage IV 32 96.9 36 88.9 33 78.8 17 82.4 31 77.4
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2.4. Associations Between VEGF-A, VEGF-C, VEGF-D and VEGFR-2, VEGFR-3 Expression in Lymph Nodes
of CRC
In order to look for the existence of some association, we matched the expression of this
angiogenic related-proteins (VEGF-A, VEGF-C, VEGF-D) with their receptors (VEGFR-2 and VEGFR-3)
in metastatic CRC lymph nodes and we observed that VEGF-C positivity was associated with VEGFR-3
positivity (p = 0.031), as well as VEGR-D positivity was associated with VEGFR-2 (p ≤ 0.001) and
VEGFR-3 (p = 0.001) positivity, Table 6.
Table 6. Assessment of associations between expression of VEGF-A, VEGF-C and VEGF-D and
the receptors VEGFR-2 and VEGFR-3 in lymph node metastasis of CRC. * Examined for statistical
significance using Fisher’s exact test (when n < 5). In bold the significant results.
VEGFR-2 VEGFR-3
n Positive (%) n p-Value n Positive (%) n p-Value
VEGF-A 39 (81.3) 48 0.649 * 58 (79.5) 73 1.000 *
VEGF-C 48 (87.3) 55 # 77 (83.7) 92 0.031 *
VEGF-D 45 (97.8) 46 0.000 * 69 (88.5) 78 0.001
n: total number of cases with and without VEGF expression; n positive (%): Total number of cases with expression
of both VEGF ligand and the VEGF-R and respective percentage. # It was not possible to establish association
between VEGF-C and VEGFR-2 expression in lymph nodes since all patients in this group have positive expression
of VEGF-C, positive VEGF-C is a constant.
2.5. Association between VEGF-A, VEGF-C, VEGF-D and VEGFR-2, VEGFR-3 Expression in CRC Primary
Tumor and Respective Lymph Nodes Metastasis
With the intention to evaluate the potential relationship of the expression of these angiogenic
factors and receptors in tumor and lymph node samples that belongs to the same patient, we analyzed
the overall results depicted in Table 7.
Table 7. Pattern of protein staining in primary tumor versus the respective metastatic lymph nodes in




VEGF-A VEGF-C VEGF-D VEGFR-2 VEGFR-3










Positive 124 93.5 0.039 121 87.6 0.002 103 80.6 0.000 57 84.2 0.021 95 78.9 0.000
VEGF-C
Positive 122 91.8 1.000 120 88.3 0.189 105 78.1 0.001 62 83.9 0.012 95 82.1 0.003
VEGFR-2
Positive 128 91.4 0.006 121 87.6 0.019 104 76.9 0.000 62 82.3 # 96 80.2 0.000
VEGFR-3
Positive 31 90.3 0.000 33 84.8 0.000 28 85.7 0.000 20 75.0 0.000 23 95.7 0.000
# It was not possible to establish association between VEGFR-2 expression in primary tumor and VEGFR-2 expression
in lymph nodes since all patients in this group have positive expression of VEGFR-2 in primary tumor.
It can be seen that VEGF-A positivity in CRC primary tumor samples associates with VEGF-A
(p = 0.039), VEGF-C (p = 0.002), VEGF-D (p ≤ 0.001), VEGFR-2 (p = 0.021) and VEGFR-3 (p ≤ 0.001)
positivity in their respective lymph node metastasis; VEGF-C in primary tumor and VEGF-D (p = 0.001),
VEGFR-2 (p = 0.012) and VEGFR-3 (p = 0.003); VEGFR-2 expression in CRC and VEGF-A (p = 0.006),
VEGF-C (p = 0.019), VEGF-D (p ≤ 0.001), VEGFR-2 (#) and VEGFR-3 (p ≤ 0.001) in their lymph nodes;
VEGFR-3 in CRC tissues and VEGF-A (p ≤ 0.001), VEGF-C (p ≤ 0.001), VEGF-D (p ≤ 0.001), VEGFR-2
(p ≤ 0.001) and VEGFR-3 (p ≤ 0.001) in lymph nodes.
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2.6. Lack of Relationship between Overall CRC Survival and Expression of VEGF-A, VEGF-C, VEGF-D,
VEGFR-2 and VEGFR-3 in CRC Lymph Nodes Metastasis
Kaplan-Meier survival curves were built to evaluate the correlation between the expression of
VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 in CRC lymph nodes metastasis and their survival
(Table 8).
Table 8. Relation between VEGF expression in CRC lymph node metastasis and survival.
Protein
Marker
N n of Deaths (%)
Average for Survival Time p
[95% CI] (Log-Rank Test)
VEGF-A
Positive 124 40 (32.26%) 65.01 [58.86–71.17]
0.748Negative 12 4 (33.33%) 57.89 [37.15–78.63]
VEGF-C
Positive 115 38 (33.04%) 63.61 [56.74–70.47]
0.824Negative 18 6 (33.33%) 65.31 [49.74–80.97]
VEGF-D
Positive 88 29 (32.95%) 62.21 [54.54–69.87]
0.688Negative 25 9 (36.00%) 53.25 [39.85–66.66]
VEGFR-2
Positive 53 10 (1.89%) 50.26 [50.22–62.31]
0.062Negative 11 5 (4.55%) 34.03 [22.00–46.06]
VEGFR-3
Positive 83 28 (3.37%) 62.81 [54.66–70.97]
0.788Negative 21 8 (3.81%) 57.17 [41.84–72.50]
When analysing the survival curves, no significant associations were found between the expression
of the different VEGF in lymph nodes of CRC and survival of the patients.
3. Discussion
There are several data highlighting the essential role of angiogenesis in tumorigenesis,
metastization and prognosis [5]. CRC growth and spread are especially dependent on angiogenesis,
where VEGF play an important role in this process [8]. However, the relationship between VEFG tumor
expression and CRC outcomes is controversial. We documented previously that the quantification
of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in primary tumor of CRC provide valuable
prognostic information with confident correlation with clinicopathological data, showing with the
principal characteristics that contribute poor survival rates and prognosis [13].
Following our earlier study insights that evaluated VEGF family expression in the primary tumor,
we sought to investigate the expression of VEGF-A, C, D and VEGFR-2 and VEGFR-3 in CRC lymph
nodes and to correlate this expression with clinical and prognostic parameters of the same patient
group [13].
Similarly to literature data, which states that VEGF-A is the most abundantly expressed ligand of
the VEGF family in primary tumor of CRC [6,8], the pattern of protein staining in lymph nodes also
showed positive expression of VEGF-A in 60% of CRC metastatic to lymph nodes. However, in our
previous study, VEGF-A expression in tumor cells was not significantly higher than its expression in
normal adjacent epithelium [13]. Other studies have shown a higher expression of VEGF-A in patients
with metastatic tumors as well as in those with non-metastatic tumors [6,9,13,17] and a significant
correlation with angio-lymphatic invasion, lymph node status and depth of invasion [8,13,18]. However,
as all patients included in our study had a histological diagnosis of colorectal adenocarcinoma associated
with positive lymph nodes, the potential comparison with these observations was impaired.
Additionally, we observed significant positive expression of VEGF-C (54.8%), VEGF-D (41.9%)
and the receptor VEGFR-3 (39.5%), all of these factors particularly involved in lymphangiogenesis
and lymph node invasion of tumors [19]. The lowest percentage of expression was observed for
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VEGFR-2 receptor (25.2%), a receptor that regulates endothelial proliferation and migration and most
significantly involved in the process of angiogenesis [19,20]. Since the expression of these factors
was exclusively focused in lymph nodes of CRC, it seems logical to have a higher percentage of
expression of factors involved in the lymphangiogenesis process (VEGF-C, D, R3). In our previous
study, when VEGF expression was compared in tumor cells and normal adjacent epithelium, only
VEGF-C appeared to be expressively overexpressed in tumor cells and VEGFR-2 showed a tendency
for an analogous association.
VEGF-A expression in CRC lymph nodes was found to be significantly related (p = 0.0001) to
the patient’s age, with patients aged 45 years or older, showing tumors with the highest expression of
VEGF-A (92.4%). However, this finding contradicts the literature data that describes a decline in the
expression of VEGF family factors with age [21–23]; this can be explicated by the fact that the number
of patients aged less than 45 years (n = 8) is much lower than the number of patients aged 45 years or
older (n = 131), so an enlargement of the sample could be useful to test this hypothesis.
It was also observed that the expressions of VEGFR-2 (p = 0.032) and VEGFR-3 (p = 0.034) receptors
in the lymph nodes of CRC patients were significantly related to cancer recurrence. Although scarce,
some literature data endorse these findings, since they assign to the presence of angiogenic cytokine
receptors an increased risk of relapse of several types of cancer [24–26]. In view of this finding,
it may be important to implement a tighter follow-up plan for patients with positive expression of
VEGFR-2 and VEGFR-3 receptors in the resected lymph nodes in order to make an earlier detection of
cancer recurrence.
We analyzed the associations between expression of VEGF-A, VEGF-C, VEGF-D and the receptors
VEGFR-2 and VEGFR-3 in CRC LNM samples and observed that VEGF-C positivity was associated
with VEGFR-3 expression (p = 0.031) and VEGR-D positive reactions were associated with VEGFR-2
(p ≤ 0.001) and VEGFR-3 (p = 0.001) positivity; this is consistent with what is reported by other
investigations showing that lymphangiogenesis induced by VEGF-C is predominantly driven by the
activation of the tyrosine kinase-linked receptor VEGFR-3 [27]. Nevertheless, VEGF-C and VEGF-D
have important roles in both angiogenesis and lymphangiogenesis, recognized as ligands of the tyrosine
kinase receptors VEGFR-2, crucial for development of the blood vasculature, but also of the lymphatic
vessels; moreover, VEGFR-3, primarily characterized as lymphangiogenic molecule, may also play
decisive role in blood vessels growth [19].
VEGFR-3, restricted to lymphatic vessels in the final stages of development [15], and its ligands
(VEGF-C and -D) stimulate lymphangiogenesis in tumors and induce proliferation and growth of new
lymphatic capillaries, enhancing the incidence of LNM [13]. This is in agreement with the present
study since all the patients with CRC included in the sample already had lymphatic spread of the
tumor with positive lymph nodes.
When analyzing VEGF’s expression and its receptors in lymph nodes and respectively primary
tumor sample, we observed a significant association between the expression of VEGF-A in cancer
tissue and the expression of VEGF-A in lymph nodes metastasis (p = 0.039). We can speculate a
potential relationship between the cytokines produced in the primary tumor and those produced by the
lymph nodes, creating an environment that supposedly promotes both tumor growth and lymphatic
dissemination. We also found an interesting association between VEGF-A positivity in CRC samples
and the expression of VEGF-C (p = 0.002), VEGF-D (p ≤ 0.001), VEGFR-2 (p = 0.021) and VEGFR-3
(p ≤ 0.001) in their respective lymph node metastasis. These findings reinforce the impression that
the VEGF-A cytokine expressed by the primary tumor favor not only the growth and development of
the primary tumor, but likewise its dissemination, stimulating the production of lymphangiogenic
factors [6,8,18].
Of note, we also found that VEGF-C expression in CRC are associated to the VEGF-D (p = 0.001),
VEGFR-2 (p = 0.012) and VEGFR-3 expression (p = 0.003) in CRC lymph node metastasis, which is
in line with the mechanism of lymphangiogenesis and spread through lymphatic invasion. In CRC,
augmented VEGF-C expression correlated with lymphatic invasion and lymph node metastasis, having
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as one of its receptors the VEGFR-3, expressed almost exclusively by lymphatic endothelium in
adulthood [28].
Finally, we also observed a remarkable association between VEGFR-2 expression in the primary
tumor and the expression of all angiogenic factors in their corresponding lymph node metastasis,
VEGF-A (p = 0.006), VEGF-C (p = 0.019), VEGF-D (p = 0.0001) and VEGFR-3 (p = 0.0001), as well as
considerable association between VEGFR-3 expression in CRC as well as the expression of all VEGFs
in the respective CRC lymph nodes infiltration: VEGF-A (p ≤ 0.001), VEGF-C (p ≤ 0.001), VEGF-D
(p ≤ 0.001), VEGFR-2 (p ≤ 0.0011) and VEGFR-3 (p ≤ 0.0011). All these data alert us to the possibility
that the production of these angiogenic factors by the lymph nodes can promote the progression
and development of the primary tumor. Seems clear the ability to improve the tumor spread by the
lymph nodes microenvironment, which reinforce the importance of its removal along with that of
the tumor, is a way to avoid its local or distant recurrence. Our finding is also in accordance with
literature that postulate that cancer cells infiltrated in lymph nodes and surrounding macrophages
as well, continues to produce VEGFs ligand and receptors molecules even in metastatic field, which
enhance the aggressiveness of the tumors and their potential of continuing dissemination of malignant
cells [29,30].
4. Materials and Methods
Population was constituted by 512 patients submitted to curative surgical intervention by CRC
between 1st January of 2005 and 1st January of 2010.
CRC and lymph node samples were collected. Final sample was constituted by 210 patients with
CRC with regional lymph node metastasis.
Data were collected prospectively, namely epidemiological data, clinical patient history, surgical
and pathology records. Survival was actualized through follow-up evaluation in medical archives.
4.1. CRC Primary Tumor and Metastasis Lymph Node Human Samples
CRC tissue samples from the 512 patients were collected. The histological type of CRC was
classified by an experienced pathologist and tumor staging was graded according to the TNM
classification, 7th edition [31]. Tissue samples of CRC LNM were selected from the previous series,
comprising 210 patients.
CRC samples and CRC LNM were included into tissue microarrays (TMAs). Prior to TMA
construction, haematoxylin and eosin sections were reviewed to select representative areas of the
tumor. Normal-adjacent tissue was also included in the TMAs for primary tumors. Each case was
represented in the TMA by at least two cores of 0.6 mm.
The study protocol was approved by the Ethics Committee of Hospital de Braga. The data of CRC
and LNM series were collected prospectively, patients were informed and signed a written consensus
for collecting data and samples collection.
4.2. Immunohistochemistry
Tissue microarray (TMA) protein expression was evaluated by immunohistochemistry. Briefly,
after de-paraffinization and rehydration, 3 µm sections were immersed in 0.01 M citrate buffer (pH 6.0)
and heated at 98 ◦C for 20 min for epitope antigen retrieval. Subsequently, endogenous peroxidase
was blocked with 0.3% hydrogen peroxide in methanol. The primary antibody incubation step take
place overnight at 4 ◦C. Visualization was developed with 3,3′-diaminobenzidine (DAKO Corporation,
Carpinteria, CA, USA) and counterstaining with Harris’s haematoxylin (Merck, Dermstadt, Germany).
Negative controls were obtained by omitting the primary antibody incubation step and tonsils were
used as positive control. Details of the procedure used for each antibody are shown in Table 9. After the
immunohistochemical procedure, the slides were evaluated and then photographed under microscope.
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Immunohistochemical Evaluation
Sections were scored semi-quantitatively for the extent and intensity of reactions: The extension
of immunoreaction was scored as follows: 0: 0% of immunoreactive cells; 1: <5% of immunoreactive
cells; 2: 5–50% of immunoreactive cells; and 3: >50% of immunoreactive cells. The intensity of staining
was classified semi-qualitatively as 0: negative; 1: weak; 2: intermediate; and 3: strong. The final score
for the immunoreaction was defined as the sum of both parameters (extent and intensity), and grouped
as negative, 0; weak, 2; moderate, 3; and strong, 4–6 [32]. For statistical purposes, moderate and
strong immunoreaction final scores were combined and considered as positive. Evaluation of VEGF
immunohistochemical expression was performed blindly by two independent observers, project
investigator and project co-supervisor, and discordant cases were discussed in order to determine a
final score.
4.3. Statistical Analysis
All data were collected and stored in an Excel PC database (Microsoft® Office Excel 2013).
Descriptive and inferential statistical analysis was performed using the Statistical Package for the
Social Science (SPSS Inc., Chicago, IL, USA), version 25.0 for Windows®.
All comparisons were examined for statistical significance using Pearson’s chi-square (X2) test
and the Fisher’s exact test (when n < 5), with the threshold for significant p-values of less than 0.05.
Differences in expression between LNM and primary CRC were analyzed by the McNemar test,
for p < 0.05. Survival curves were determined for overall survival by the Kaplan–Meier method and
the log-rank test.
5. Conclusions
The current study stablished new information that revealing the expression of the VEGF family
and receptors is also increased in the lymph nodes metastasis. Also, the association between the
expression of VEGFR-2and VEGFR-3 in lymph nodes with CRC relapse reveals its important negative
impact on the worse prognosis of the patient.
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